LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Verve Therapeutics Inc

Cerrado

4.64 8.41

Resumen

Variación precio

24h

Actual

Mínimo

4.22

Máximo

4.7

Métricas clave

By Trading Economics

Ingresos

98K

-50M

Ventas

6.2M

13M

BPA

-0.58

Margen de beneficio

-382.531

Empleados

274

EBITDA

789K

-54M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+485.85% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-207M

388M

Apertura anterior

-3.77

Cierre anterior

4.64

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Verve Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 may 2025, 19:39 UTC

Principales Movimientos del Mercado

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 may 2025, 23:18 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 may 2025, 22:30 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- Update

16 may 2025, 21:56 UTC

Charlas de Mercado

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 may 2025, 21:56 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 may 2025, 21:54 UTC

Principales Noticias

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 may 2025, 21:22 UTC

Charlas de Mercado

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 may 2025, 21:17 UTC

Charlas de Mercado

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 may 2025, 21:17 UTC

Principales Noticias

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 may 2025, 21:05 UTC

Charlas de Mercado

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 may 2025, 20:55 UTC

Adquisiciones, fusiones, absorciones

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 may 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

16 may 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 may 2025, 20:37 UTC

Principales Noticias

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 may 2025, 20:33 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 may 2025, 20:30 UTC

Adquisiciones, fusiones, absorciones

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 may 2025, 20:18 UTC

Principales Noticias

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 may 2025, 20:16 UTC

Principales Noticias

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 may 2025, 20:15 UTC

Ganancias

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 may 2025, 20:11 UTC

Adquisiciones, fusiones, absorciones

Henry Schein: William K. Daniel Joins Board

16 may 2025, 20:10 UTC

Adquisiciones, fusiones, absorciones

Henry Schein: Strategic Investment by KKR Completed

16 may 2025, 20:05 UTC

Adquisiciones, fusiones, absorciones

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 may 2025, 19:38 UTC

Charlas de Mercado

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 may 2025, 19:07 UTC

Charlas de Mercado

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 may 2025, 18:51 UTC

Principales Noticias

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 may 2025, 18:41 UTC

Adquisiciones, fusiones, absorciones

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 may 2025, 18:37 UTC

Charlas de Mercado

Gold Futures End Week on Negative Note -- Market Talk

16 may 2025, 18:35 UTC

Principales Noticias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 may 2025, 18:32 UTC

Principales Noticias

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 may 2025, 18:28 UTC

Charlas de Mercado

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Comparación entre iguales

Cambio de precio

Verve Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

485.85% repunte

Estimación a 12 meses

Media 25.25 USD  485.85%

Máximo 39 USD

Mínimo 15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Verve Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.1501 / 5.16Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.